Małgorzata Wach
About
Małgorzata Wach is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology.
According to data from OpenAlex, Małgorzata Wach has authored 35 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Genetics, 15 papers in Pathology and Forensic Medicine and 14 papers in Hematology. Recurrent topics in Małgorzata Wach's work include Chronic Lymphocytic Leukemia Research (24 papers), Lymphoma Diagnosis and Treatment (14 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Małgorzata Wach is often cited by papers focused on Chronic Lymphocytic Leukemia Research (24 papers), Lymphoma Diagnosis and Treatment (14 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Małgorzata Wach collaborates with scholars based in Poland, United States and Canada. Małgorzata Wach's co-authors include Wojciech Jurczak, Árpád Illés, Martin Šimkovič, Daniel Lysák, Paolo Ghia, Sean Dolan, Abraham Jacob, Javier de la Serna, Andrzej Pluta and Eric J. Avery and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Małgorzata Wach
33 papers receiving 691 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Małgorzata Wach Poland | 11 | 573 | 448 | 221 | 199 | 118 | 35 | 695 | ||
| Andrew Lipsky United States | 8 | 566 1.0× | 403 0.9× | 203 0.9× | 260 1.3× | 103 0.9× | 23 | 694 | ||
| Saad M. B. Rassam United Kingdom | 8 | 495 0.9× | 456 1.0× | 142 0.6× | 285 1.4× | 138 1.2× | 15 | 686 | ||
| Paul Moreton United Kingdom | 12 | 712 1.2× | 649 1.4× | 160 0.7× | 425 2.1× | 104 0.9× | 21 | 872 | ||
| Sasanka M. Handunnetti Australia | 12 | 555 1.0× | 498 1.1× | 172 0.8× | 149 0.7× | 293 2.5× | 25 | 739 | ||
| Indu Lal United States | 6 | 518 0.9× | 338 0.8× | 372 1.7× | 290 1.5× | 119 1.0× | 14 | 787 | ||
| Myriam Mendila Germany | 9 | 778 1.4× | 752 1.7× | 163 0.7× | 390 2.0× | 148 1.3× | 16 | 947 | ||
| Gerhard Postner Austria | 7 | 354 0.6× | 324 0.7× | 109 0.5× | 127 0.6× | 61 0.5× | 8 | 613 | ||
| Yuh Shan Lee Singapore | 8 | 376 0.7× | 350 0.8× | 93 0.4× | 244 1.2× | 115 1.0× | 17 | 518 | ||
| Niels Smedegaard Andersen Denmark | 13 | 313 0.5× | 499 1.1× | 222 1.0× | 243 1.2× | 412 3.5× | 38 | 834 | ||
| Jose Iturraspe United States | 12 | 208 0.4× | 280 0.6× | 164 0.7× | 227 1.1× | 128 1.1× | 13 | 558 |
Countries citing papers authored by Małgorzata Wach
Since
Specialization
Citations
This map shows the geographic impact of Małgorzata Wach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Małgorzata Wach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Małgorzata Wach more than expected).
Fields of papers citing papers by Małgorzata Wach
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Małgorzata Wach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Małgorzata Wach. The network helps show where Małgorzata Wach may publish in the future.
Co-authorship network of co-authors of Małgorzata Wach
This figure shows the co-authorship network connecting the top 25 collaborators of Małgorzata Wach. A scholar is included among the top collaborators of Małgorzata Wach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Małgorzata Wach. Małgorzata Wach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Brown, Jennifer R., John F. Seymour, Wojciech Jurczak, et al.. (2025). Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. New England Journal of Medicine. 392(8). 748–762.
2.
Brown, Jennifer R., John F. Seymour, Wojciech Jurczak, et al.. (2024). Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial. Blood. 144(Supplement 1). 1009–1009.
3.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2022). Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere. 6(12). e801–e801.
4.
Ghia, Paolo, Małgorzata Wach, Daniel Lysák, et al.. (2022). P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP. HemaSphere. 6. 566–567.
5.
Jurczak, Wojciech, Andrzej Pluta, Małgorzata Wach, et al.. (2021). Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 393–393.
6.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 38(25). 2849–2861.
7.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results. Clinical Lymphoma Myeloma & Leukemia. 20. S220–S221.
8.
Montillo, Marco, Árpád Illés, Tadeusz Robak, et al.. (2019). Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. Health and Quality of Life Outcomes. 17(1). 173–173.
9.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2019). Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. Clinical Lymphoma Myeloma & Leukemia. 19. S280–S281.
10.
Jones, Jeffrey A., Tadeusz Robak, Jennifer R. Brown, et al.. (2017). Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. The Lancet Haematology. 4(3). e114–e126.
11.
Szczepanek, Dariusz, Ewa Wąsik‐Szczepanek, Agnieszka Szymczyk, et al.. (2017). Central nervous involvement by chronic lymphocytic leukaemia. Neurologia i Neurochirurgia Polska. 52(2). 228–234.
12.
Jones, Jeffrey A., Tadeusz Robak, Małgorzata Wach, et al.. (2016). Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 34(15_suppl). 7515–7515.
13.
Cioch, Maria, et al.. (2016). Autologous Hematopoietic Stem Cell Transplantation for Adults With Acute Myeloid Leukemia. Transplantation Proceedings. 48(5). 1814–1817.
14.
Cioch, Maria, et al.. (2014). Biosimilar Granulocyte Colony-Stimulating Factor Is Effective in Reducing the Duration of Neutropenia After Autologous Peripheral Blood Stem Cell Transplantation. Transplantation Proceedings. 46(8). 2882–2884.
15.
Wach, Małgorzata, Maria Cioch, Marek Hus, et al.. (2011). Treatment of multiple myeloma patients with autologous stem cell transplantation — a fresh analysis. Folia Histochemica et Cytobiologica. 49(2). 248–254.
16.
Kotwica-Mojzych, Katarzyna, Maria Cioch, Małgorzata Wach, et al.. (2011). Use of Biosimilar G-CSF Is Effective After Autologous Bone Marrow Transplantation. Blood. 118(21). 5321–5321.
17.
Hołowiecki, Jerzy, Sebastian Grosicki, Maria Saduś‐Wojciechowska, et al.. (2005). Addition of Cladribine to Induction/Consolidation Regimen Does Not Impair Peripheral Blood Stem Cell Mobilization and Bone Marrow Harvest for Autotransplantation in Acute Myeloid Leukemia Patients. Transplantation Proceedings. 37(10). 4482–4487.
18.
Wrzesień‐Kuś, Agata, Tadeusz Robak, Agnieszka Wierzbowska, et al.. (2005). A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Annals of Hematology. 84(9). 557–564.
19.
Wach, Małgorzata, et al.. (2003). Neutropenic enterocolitis: a serious complication during the treatment of acute leukemias. Annals of Hematology. 83(8). 522–6.
20.
Wach, Małgorzata, Anna Dmoszyńska, Danuta Skomra, Ewa Wąsik‐Szczepanek, & Justyna Szumiło. (2001). Intravascular B-cell lymphoma in a 38-year-old woman: a case report. Annals of Hematology. 80(4). 224–227.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Andrew Lipsky Breakdown of academic impact, for papers by Saad M. B. Rassam Breakdown of academic impact, for papers by Paul Moreton Breakdown of academic impact, for papers by Sasanka M. Handunnetti Breakdown of academic impact, for papers by Indu Lal Breakdown of academic impact, for papers by Myriam Mendila Breakdown of academic impact, for papers by Gerhard Postner Breakdown of academic impact, for papers by Yuh Shan Lee Breakdown of academic impact, for papers by Niels Smedegaard Andersen Breakdown of academic impact, for papers by Jose Iturraspe